Ann M Arvin

List of Publications by Year
in descending order

107 papers	4,994 citations	126708 33 h-index	102304 66 g-index
116 all docs	116 docs citations	116 times ranked	6193 citing authors

#	Article	IF	Citations
1	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. PLoS Pathogens, 2021, 17, e1008961.	2.1	12
2	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	13.7	260
3	Target highlights in <scp>CASP14</scp>: Analysis of models by structure providers. Proteins: Structure, Function and Bioinformatics, 2021, 89, 1647-1672.	1.5	27
4	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. , 2021, 17, e1008961.		0
5	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. , 2021, 17, e1008961.		0
6	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. , 2021, 17, e1008961.		0
7	The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. , 2021, 17, e1008961.		0
8	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	5.8	204
9	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 2020, 584, 353-363.	13.7	413
10	A glycoprotein B-neutralizing antibody structure at 2.8â€‰Ã… uncovers a critical domain for herpesvirus fusion initiation. Nature Communications, 2020, 11, 4141.	5.8	23
11	Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer. Open Forum Infectious Diseases, 2020, 7, ofaa172.	0.4	6
12	Deletion of Herpes Simplex Virus 1 MicroRNAs miR-H1 and miR-H6 Impairs Reactivation. Journal of Virology, 2020, 94, .	1.5	16
13	Varicella-zoster virus: molecular controls of cell fusion-dependent pathogenesis. Biochemical Society Transactions, 2020, 48, 2415-2435.	1.6	16
14	Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion. PLoS Pathogens, 2020, 16, e1009022.	2.1	5
15	The latency-associated transcript locus of herpes simplex virus 1 is a virulence determinant in human skin. PLoS Pathogens, 2020, 16, e1009166.	2.1	11
16	Title is missing!. , 2020, 16, e1009166.		0
17	Title is missing!. , 2020, 16, e1009166.		0
18	Title is missing!. , 2020, 16, e1009166.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 16, e1009166.		0
20	Title is missing!. , 2020, 16, e1009166.		0
21	Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion. , 2020, 16, e1009022.		0
22	Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion. , 2020, 16, e1009022.		0
23	Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion. , 2020, 16, e1009022.		0
24	Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion. , 2020, 16, e1009022.		0
25	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infectious Diseases, The, 2019, 19, 1001-1012.	4.6	25
26	Will Measles Virus or Humanity Win the International â€œFitnessâ€•Challenge?. Annual Review of Virology, 2019, 6, iii-vii.	3.0	0
27	Age-Associated Differences in Infection of Human Skin in the SCID Mouse Model of Varicella-Zoster Virus Pathogenesis. Journal of Virology, 2018, 92, .	1.5	9
28	HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. PLoS ONE, 2018, 13, e0206365.	1.1	0
29	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 2116-2127.	6.3	79
30	The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology, 2018, 523, 110-120.	1.1	9
31	Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. Cell Reports, 2017, 20, 984-998.	2.9	66
32	Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection. Journal of Virology, 2017, 91, .	1.5	15
33	The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection. Journal of Virology, 2017, 91, .	1.5	20
34	Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients. Open Forum Infectious Diseases, 2017, 4, S60-S60.	0.4	2
35	Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis. Current Clinical Microbiology Reports, 2016, 3, 204-215.	1.8	39
36	Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication<i>In Vitro</i>and Skin Pathogenesis<i>In Vivo</i>. Journal of Virology, 2016, 90, 8686-8697.	1.5	12

#	Article	IF	Citations
37	Role for the Î±V Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection. Journal of Virology, 2016, 90, 7567-7578.	1.5	23
38	Neuronal Subtype and Satellite Cell Tropism Are Determinants of Varicella-Zoster Virus Virulence in Human Dorsal Root Ganglia Xenografts In Vivo. PLoS Pathogens, 2015, 11, e1004989.	2.1	30
39	Autophagic flux without a block differentiates varicella-zoster virus infection from herpes simplex virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 256-261.	3.3	42
40	Varicella-zoster virus (VZV) origin of DNA replication oriS influences origin-dependent DNA replication and flanking gene transcription. Virology, 2015, 481, 179-186.	1.1	3
41	A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6056-6061.	3.3	44
42	Varicella-Zoster Virus Infections in Patients Treated With Fingolimod. JAMA Neurology, 2015, 72, 31.	4.5	142
43	Differential effects of Sp cellular transcription factors on viral promoter activation by varicella-zoster virus (VZV) IE62 protein. Virology, 2015, 485, 47-57.	1.1	6
44	The Cytoplasmic Domain of Varicella-Zoster Virus Glycoprotein H Regulates Syncytia Formation and Skin Pathogenesis. PLoS Pathogens, 2014, 10, e1004173.	2.1	37
45	Molecular mechanisms of varicella zoster virus pathogenesis. Nature Reviews Microbiology, 2014, 12, 197-210.	13.6	319
46	Cellular transcription factor YY1 mediates the varicella-zoster virus (VZV) IE62 transcriptional activation. Virology, 2014, 449, 244-253.	1.1	7
47	Herpes Simplex Virus 1 Tropism for Human Sensory Ganglion Neurons in the Severe Combined Immunodeficiency Mouse Model of Neuropathogenesis. Journal of Virology, 2013, 87, 2791-2802.	1.5	25
48	An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1911-1916.	3.3	38
49	Structureâ€“function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18412-18417.	3.3	44
50	Mutagenesis of Varicella-Zoster Virus Glycoprotein I (gI) Identifies a Cysteine Residue Critical for gE/gI Heterodimer Formation, gI Structure, and Virulence in Skin Cells. Journal of Virology, 2011, 85, 4095-4110.	1.5	17
51	Analysis of the Functions of Glycoproteins E and I and Their Promoters During VZV Replication In Vitro and in Skin and T-Cell Xenografts in the SCID Mouse Model of VZV Pathogenesis. Current Topics in Microbiology and Immunology, 2010, 342, 129-146.	0.7	9
52	Varicella-Zoster Virus T Cell Tropism and the Pathogenesis of Skin Infection. Current Topics in Microbiology and Immunology, 2010, 342, 189-209.	0.7	75
53	Anti-Glycoprotein H Antibody Impairs the Pathogenicity of Varicella-Zoster Virus in Skin Xenografts in the SCID Mouse Model. Journal of Virology, 2010, 84, 141-152.	1.5	25
54	Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 282-287.	3.3	46

#	Article	IF	Citations
55	Mutagenesis of Varicella-Zoster Virus Glycoprotein B: Putative Fusion Loop Residues Are Essential for Viral Replication, and the Furin Cleavage Motif Contributes to Pathogenesis in Skin Tissue In Vivo. Journal of Virology, 2009, 83, 7495-7506.	1.5	56
56	Deletion of the First Cysteine-Rich Region of the Varicella-Zoster Virus Glycoprotein E Ectodomain Abolishes the gE and gI Interaction and Differentially Affects Cell-Cell Spread and Viral Entry. Journal of Virology, 2009, 83, 228-240.	1.5	37
57	Mechanisms of Varicella-Zoster Virus Neuropathogenesis in Human Dorsal Root Ganglia. Journal of Virology, 2008, 82, 3971-3983.	1.5	111
58	Humoral and Cellular Immunity to Varicellaâ€Zoster Virus: An Overview. Journal of Infectious Diseases, 2008, 197, S58-S60.	1.9	138
59	The pathogenesis of varicella-zoster virus neurotropism and infection. , 2008, , 225-250.		8
60	A Self-Excisable Infectious Bacterial Artificial Chromosome Clone of Varicella-Zoster Virus Allows Analysis of the Essential Tegument Protein Encoded by <i>ORF9</i>. Journal of Virology, 2007, 81, 13200-13208.	1.5	118
61	Control of Varicella. Pediatric Infectious Disease Journal, 2006, 25, 475-476.	1.1	54
62	Essential Functions of the Unique N-Terminal Region of the Varicella-Zoster Virus Glycoprotein E Ectodomain in Viral Replication and in the Pathogenesis of Skin Infection. Journal of Virology, 2006, 80, 9481-9496.	1.5	58
63	Investigations of the pathogenesis of Varicella zoster virus infection in the SCIDhu mouse model. Herpes: the Journal of the IHMF, 2006, 13, 75-80.	0.3	13
64	Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6490-6495.	3.3	133
65	Aging, Immunity, and the Varicellaâ€"Zoster Virus. New England Journal of Medicine, 2005, 352, 2266-2267.	13.9	249
66	Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee. Clinical Infectious Diseases, 2004, 39, 233-239.	2.9	302
67	Functions of the C-Terminal Domain of Varicella-Zoster Virus Glycoprotein E in Viral Replication In Vitro and Skin and T-Cell Tropism In Vivo. Journal of Virology, 2004, 78, 12406-12415.	1.5	54
68	Antiviral therapy for varicella and herpes zoster. Seminars in Pediatric Infectious Diseases, 2002, 13, 12-21.	1.7	58
69	Immune Responses to Measles and Mumps Vaccination of Infants at 6, 9, and 12 Months. Journal of Infectious Diseases, 2001, 184, 817-826.	1.9	213
70	Granulysin Blocks Replication of Varicella-Zoster Virus and Triggers Apoptosis of Infected Cells. Viral Immunology, 2001, 14, 125-133.	0.6	51
71	Intravenous ribavirin therapy for adenovirus pneumonia. , 2000, 29, 64-73.		42
72	Varicella and herpes zoster in pregnancy and the newborn. , 2000, , 317-348.		44

#	Article	IF	Citations
73	Clinical manifestations of herpes zoster. , 2000, , 246-275.		29
74	Molecular evolution of alphaherpesviruses. , 2000, , 25-50.		8
75	DNA replication. , 2000, , 51-73.		13
76	Viral proteins. , 2000, , 74-104.		25
77	Pathogenesis of primary infection. , 2000, , 105-122.		8
78	Pathogenesis of latency and reactivation. , 2000, , 123-141.		15
79	Host response to primary infection. , 2000, , 142-156.		10
80	Host response during latency and reactivation. , 2000, , 157-168.		0
81	Animal models of infection. , 2000, , 169-184.		3
82	Epidemiology of varicella. , 2000, , 187-205.		25
83	Clinical manifestations of varicella. , 2000, , 206-219.		11
84	Epidemiology of herpes zoster. , 2000, , 220-245.		9
85	Ophthalmic zoster. , 2000, , 276-298.		5
86	Postherpetic neuralgia and other neurologic complications. , 2000, , 299-316.		1
87	Laboratory diagnosis of infection. , 2000, , 351-382.		10
88	Treatment of varicella. , 2000, , 385-395.		3
89	Treatment of herpes zoster. , 2000, , 396-411.		1
90	Management of postherpetic pain. , 2000, , 412-427.		1

#	Article	IF	Citations
91	Passive antibody prophylaxis. , 2000, , 428-441.		1
92	Development of the Oka vaccine. , 2000, , 442-459.		6
93	Primary immunization against varicella. , 2000, , 460-476.		7
94	Prevention of nosocomial transmission. , 2000, , 477-499.		3
95	Immunization against herpes zoster. , 2000, , 500-519.		1
96	Frequencies of Memory T Cells Specific for Varicellaâ€Zoster Virus, Herpes Simplex Virus, and Cytomegalovirus by Intracellular Detection of Cytokine Expression. Journal of Infectious Diseases, 2000, 181, 859-866.	1.9	188
97	The Epidemiology of Neonatal Herpes Simplex Virus Infections in California from 1985 to 1995. Journal of Infectious Diseases, 1999, 180, 199-202.	1.9	75
98	Varicella-zoster virus immune evasion. Immunological Reviews, 1999, 168, 143-156.	2.8	50
99	Isolation and Utilization of Human Dendritic Cells from Peripheral Blood to Assay an In Vitro Primary Immune Response to Varicellaâ€Zoster Virus Peptides. Journal of Infectious Diseases, 1998, 178, S39-S42.	1.9	13
100	Attenuation of the Vaccine Oka Strain of Varicella-Zoster Virus and Role of Glycoprotein C in Alphaherpesvirus Virulence Demonstrated in the SCID-hu Mouse. Journal of Virology, 1998, 72, 965-974.	1.5	204
101	Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella. Journal of Medical Virology, 1994, 43, 69-71.	2.5	34
102	Herpes Simplex Virus Infections: The Genital Tract and the Newborn. Pediatrics in Review, 1992, 13, 107-111.	0.2	3
103	Humoral and Cell-Mediated Immunity in Neonates with Herpes Simplex Virus Infection. Journal of Infectious Diseases, 1987, 155, 28-37.	1.9	129
104	Acid Labile Î±-interferon in sera and synovial fluids from patients with juvenile arthritis. Arthritis and Rheumatism, 1984, 27, 582-585.	6.7	23
105	Reasons for the Absence of a History of Recurrent Genital Infections in Mothers of Neonates Infected with Herpes Simplex Virus. Pediatrics, 1984, 73, 188-193.	1.0	114
106	Varicella-zoster Virus Infections. , 0, , 1388-1409.		5
107	Genital Herpesvirus Infections: Rationale for a Vaccine Strategy. , 0, , 259-267.		0